Background: A poor patient adherence often limits the real-world effectiveness of an oral disease-modifying therapy (DMT) for multiple sclerosis (MS). In the present study, we aimed to map patient preferences, attitudes toward treatment, and quality of life to identify the predictors of non-adherence to teriflunomide. Methods: This was a single-arm, non-interventional, multicenter study (Czech Act 378/2007 Coll.) consisting of three visits: the first at treatment initiation (teriflunomide 14 mg), and then after 3 and 9 months of therapy. We enrolled both DMT-naïve and patients who had undergone a DMT diagnosed with a clinically isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS). The functional status and MS activity were estimated using the Expanded Disability Status Scale (EDSS) and annualized relapse rate (ARR); the quality of life via the Multiple Sclerosis Impact Scale (MSIS-29); the medication adherence with the Morisky Medication Adherence Scale (MMAS-8); the confidence in the ability to take medications by the Self-Efficacy for Appropriate Medication Score (SEAMS); and the attitude to the therapy via the Beliefs about Medicines Questionnaire (BMQ). After nine months of therapy, we predicted the adherence to teriflunomide (MMAS-8) by fitting a multivariate ordinal logistic model with EDSS changes, gender, previous DMT, MSIS-29, BMQ, and SEAMS as the explanatory variables. Results: Between 2018 and 2019, 114 patients were enrolled at 10 sites in the Czech Republic. The mean age was 41.2 years, 64.8% were diagnosed with a CIS, 52.4% were DMT-naïve, and 98.1% of patients preferred an oral administration at the baseline. The mean EDSS baseline was 1.97 and remained constant during the 9 months of therapy. The ARR baseline was 0.72 and dropped to 0.19 and 0.15 after 3 and 9 months, respectively. Despite a more than 4-fold higher ARR baseline, the treatment-naïve patients achieved an ARR at 9 months comparable with those previously treated. There were ten non-serious adverse reactions. After nine months of teriflunomide therapy, 63.3%, 21.2%, and 15.4% of patients had a high, medium, and low adherence, respectively, as per the MMAS-8; 100% of patients preferred an oral administration. The SEAMS score (odds ratio (OR) = 0.91; p = 0.013) and previous DMT (OR = 4.28; p = 0.005) were the only significant predictors of non-adherence. The disability, the quality of life, and beliefs about medicines had no measurable effect on adherence. Conclusion: After nine months of teriflunomide therapy, both the disability and quality of life remained stable; the relapse rate significantly decreased, 63.3% of patients had a high adherence, and 100% of patients preferred an oral administration. A low adherence was associated with previous DMT experiences and a low self-efficacy for the appropriate medication (i.e., the confidence in one's ability to take medication correctly).

1st Department of Neurology St Anne's University Hospital Pekařská 664 53 60200 Brno Czech Republic

Medical Informatics 1st Medical Faculty Charles University Kateřinská 1660 32 12000 Prague Czech Republic

Pharmacology Department Faculty of Medicine Masaryk University Kamenice 753 5 62500 Brno Czech Republic

Sanofi Evropská 846 176a 16000 Prague Czech Republic

Value Outcomes Ltd Vaclavska 316 12 12000 Prague Czech Republic

Zobrazit více v PubMed

Wallin M.T., Culpepper W.J., Nichols E., Bhutta Z.A., Gebrehiwot T.T., Hay S.I., Khalil I.A., Krohn K.J., Liang X., Naghavi M., et al. Global, regional, and national burden of multiple sclerosis 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:269–285. doi: 10.1016/S1474-4422(18)30443-5. PubMed DOI PMC

Simpson S., Blizzard L., Otahal P., Van der Mei I., Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: A meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2011;82:1132–1141. doi: 10.1136/jnnp.2011.240432. PubMed DOI

He D., Zhang C., Zhao X., Zhang Y., Dai Q., Li Y., Chu L. Teriflunomide for multiple sclerosis. [(accessed on 7 December 2021)];Cochrane Database Syst. Rev. 2016 3:8. doi: 10.1002/14651858.CD009882.pub3. Available online: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009882.pub3/full. PubMed DOI PMC

Nicholas J.A., Edwards N.C., Edwards R.A., Dellarole A., Grosso M., Phillips A.L. Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: A systematic review and meta-analysis. BMC Neurol. 2020;20:281. doi: 10.1186/s12883-020-01830-0. PubMed DOI PMC

Munsell M., Frean M., Menzin J., Phillips A.L. An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug. Patient Prefer. Adherence. 2016;11:55–62. doi: 10.2147/PPA.S118107. PubMed DOI PMC

Zhou T., Guan H., Wang L., Zhang Y., Rui M., Ma A. Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review. Front. Public Health. 2021;9:675523. doi: 10.3389/fpubh.2021.675523. PubMed DOI PMC

Aubagio European Public Assessment Report EMEA/H/002514-IG1386, Updated 27/08/2021. [(accessed on 7 December 2021)]. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio.

Vermersch P., Czlonkowska A., Grimaldi L.M., Confavreux C., Comi G., Kappos L., Olsson T.P., Benamor M., Bauer D., Truffinet P., et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: A randomised, controlled phase 3 trial. Mult. Scler. J. 2014;20:705–716. doi: 10.1177/1352458513507821. PubMed DOI

O’Connor P., Wolinsky J.S., Confavreux C., Comi G., Kappos L., Olsson T.P., Benzerdjeb H., Truffinet P., Wang L., Miller A., et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 2011;365:1293–1303. doi: 10.1056/NEJMoa1014656. PubMed DOI

Confavreux C., O’Connor P., Comi G., Freedman M.S., Miller A.E., Olsson T.P., Wolinsky J.S., Bagulho T., Delhay J.-L., Dukovic D., et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:247–256. doi: 10.1016/S1474-4422(13)70308-9. PubMed DOI

Miller A.E., Wolinsky J.S., Kappos L., Comi G., Freedman M.S., Olsson T.P., Bauer D., Benamor M., Truffinet P., O’Connor P.W., et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:977–986. doi: 10.1016/S1474-4422(14)70191-7. PubMed DOI

Bayas A., Mäurer M. Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: Patient preference and adherence. Patient Prefer. Adherence. 2015;9:265. doi: 10.2147/PPA.S61651. PubMed DOI PMC

Visser L.A., Louapre C., Uyl-de Groot C.A., Redekop W.K. Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review. Mult. Scler. Relat. Disord. 2020;39:101929. doi: 10.1016/j.msard.2020.101929. PubMed DOI

Vermersch P., Suchet L., Colamarino R., Laurendeau C., Detournay B. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014–2017. Mult. Scler. Relat. Disord. 2020;46:102521. doi: 10.1016/j.msard.2020.102521. PubMed DOI

Lahdenperä S., Soilu-Hänninen M., Kuusisto H., Atula S., Junnila J., Berglund A. Medication adherence/persistence among patients with active multiple sclerosis in Finland. Acta Neurol. Scand. 2020;142:605–612. doi: 10.1111/ane.13301. PubMed DOI PMC

Prosperini L., Cortese A., Lucchini M., Boffa L., Borriello G., Buscarinu M.C., Capone F., Centonze D., De Fino C., De Pascalis D., et al. Exit strategies for “needle fatigue” in multiple sclerosis: A propensity score-matched comparison study. J. Neurol. 2020;267:694–702. doi: 10.1007/s00415-019-09625-1. PubMed DOI

Liu Z., Liao Q., Wen H., Zhang Y. Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis. Autoimmun. Rev. 2021;20:102826. doi: 10.1016/j.autrev.2021.102826. PubMed DOI

Buron M.D., Chalmer T.A., Sellebjerg F., Frederiksen J., Góra M.K., Illes Z., Kant M., Mezei Z., Petersen T., Rasmussen P.V., et al. Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study. Neurology. 2019;92:e1811–e1820. doi: 10.1212/WNL.0000000000007314. PubMed DOI PMC

Kalincik T., Havrdova E.K., Horakova D., Izquierdo G., Prat A., Girard M., Duquette P., Grammond P., Onofrj M., Lugaresi A., et al. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2019;90:458–468. doi: 10.1136/jnnp-2018-319831. PubMed DOI

Hillert J., Tsai J.A., Nouhi M., Glaser A., Spelman T. A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry. Mult. Scler. 2022;28:13524585211019648. doi: 10.1177/13524585211019649. PubMed DOI PMC

de Sèze J., Devy R., Planque E., Delabrousse-Mayoux J.P., Vandhuick O., Kabir M., Gherib A. Fatigue in teriflunomide-treated patients with relapsing remitting multiple sclerosis in the real-world Teri-FAST study. Mult. Scler. Relat. Disord. 2021;47:102659. doi: 10.1016/j.msard.2020.102659. PubMed DOI

Nazareth T., Friedman H.S., Navaratnam P., Herriott D.A., Ko J.J., Barr P., Sasane R. Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: A retrospective medical record review. BMC Neurol. 2016;16:187. doi: 10.1186/s12883-016-0698-9. PubMed DOI PMC

Vermersch P., Oh J., Cascione M., Oreja-Guevara C., Gobbi C., Travis L.H., Myhr K.-M., Coyle P.K. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. Mult. Scler. Relat. Disord. 2020;43:102158. doi: 10.1016/j.msard.2020.102158. PubMed DOI

Pust G.E.A., Untiedt B., Weierstall-Pust R., Randerath J., Barabasch A., Rahn A.C., Heesen C. Medication beliefs in first-line and second-line treated multiple sclerosis patients. Mult. Scler. Relat. Disord. 2020;42:102144. doi: 10.1016/j.msard.2020.102144. PubMed DOI

Yoon E.L., Cheong W.L. Adherence to oral disease-modifying therapy in multiple sclerosis patients: A systematic review. Mult. Scler. Relat. Disord. 2019;28:104–108. doi: 10.1016/j.msard.2018.12.025. PubMed DOI

Kołtuniuk A., Chojdak-Łukasiewicz J. Adherence to Therapy in Patients with Multiple Sclerosis—Review. Int. J. Environ. Res. Public. Health. 2022;19:2203. doi: 10.3390/ijerph19042203. PubMed DOI PMC

von Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., Vandenbroucke J.P. STROBE Initiative The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. J. Clin. Epidemiol. 2008;61:344–349. doi: 10.1016/j.jclinepi.2007.11.008. PubMed DOI

Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) Neurology. 1983;33:1444–1452. doi: 10.1212/WNL.33.11.1444. PubMed DOI

Hobart J., Lamping D., Fitzpatrick R., Riazi A., Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure. Brain. 2001;124:962–973. doi: 10.1093/brain/124.5.962. PubMed DOI

De las Cuevas C., Peñate W. Psychometric properties of the eight-item Morisky Medication Adherence Scale (MMAS-8) in a psychiatric outpatient setting. Int. J. Clin. Health Psychol. IJCHP. 2015;15:121–129. doi: 10.1016/j.ijchp.2014.11.003. PubMed DOI PMC

Risser J., Jacobson T.A., Kripalani S. Development and psychometric evaluation of the Self-efficacy for Appropriate Medication Use Scale (SEAMS) in low-literacy patients with chronic disease. J. Nurs. Meas. 2007;15:203–219. doi: 10.1891/106137407783095757. PubMed DOI

Svarstad B.L., Chewning B.A., Sleath B.L., Claesson C. The Brief Medication Questionnaire: A tool for screening patient adherence and barriers to adherence. Patient Educ. Couns. 1999;37:113–124. doi: 10.1016/S0738-3991(98)00107-4. PubMed DOI